Truscreen Group Ltd. · NZX:TRU
Truscreen — Shareholder Meeting (September 2024)
54 slides from Truscreen's shareholder meeting presentation, Sep 3, 2024
Slide 1: A World Without Cervical Cancer – AGM September 2024
For personal use only TruScreen A World Without Cervical Cancer AGM September 2024 Auckland, New Zealand Marty Dillon, CEO
Slide 2: Agenda
⚫ Who is TruScreen For personal use only ⚫ Key achievements in financial year 2024 TruScreen ⚫ Outlook and goals for FY 2025 A Growth Company ⚫ Market Expansion ⚫ Technology Improvement, COGS and Cost Reduction ⚫ Q&A ⚫ Appendix: TruScreen Technology 2
Slide 3: Who is TruScreen
For personal use only Who is TruScreen 3
Slide 4: Who is TruScreen
TruScreen Group Ltd is listed on both the Australian (ASX) and New Shares on Issue: Zealand (NZX) stock 552,591,116 For personal use only exchanges, with a common Who is TruScreen ticker code of TRU. TruScreen Group Ltd is a Market Capitalisation at revenue generating Life 28 August 2024: Science co
Slide 5: Recurring Revenue Model
Recurring Revenue Model The TruScreen DISPOSABLE Single For personal use only The TruScreen Real Time Use Sensor (SUS) – a consumable Cervical Cancer Screening product delivering recurring DEVICE revenue. For each patient screened with the TruScreen device a new disposable Single Use Sensor must be
Slide 6: For personal use only
• Lean headquarters • Recurring revenue stream from consumable SUS • Intellectual Property For personal use only • Service & Manufacturing Effective co-invest model Distribution Network with global distribution Local knowledge and influence End-user management End Users • Public and private hospital
Slide 7: World Class technology made simple
TruScreen World Class technology made simple Handheld device Real-time, AI-enabled, primary cervical For personal use only cancer screening device for detection of pre- cancerous and cancerous cervical tissue ⚫ Optical and electrical measurements painlessly detect abnormalities in cervical tissue ⚫
Slide 8: Key Achievements
For personal use only Key Achievements 8
Slide 9: FY2024 Financial Results
FY2024 Financial Results ⚫ Sales increased 27% YOY For personal use only KEY FINANCIALS FY 22 FY 23 FY 24 NZD (m) Actual Actual Actual Sales 1.7 1.66 2.1 ⚫ SUS Sales increased 25% YOY Total Revenue 2.7 2.2 2.6 ⚫ Revenue increased 18% YOY COGS 1.3 1.3 1.4 R&D 1.5 0.9 0.9 ⚫ EBITDA improved 15% YOY EBI
Slide 10: Key Achievements FY2024/25
For personal use only Key Achievements In March 2024 TruScreen Group Limited closed a NZD $2.6m rights issue and FY2024/25 placement confirming the markets confidence in our growth strategy. Non Executive Chairman, Tony Ho “this is an outstanding result and demonstrated the confidence that investors
Slide 11: Outlook strategy and goals FY2025
For personal use only Outlook strategy and goals FY2025 11
Slide 12: Outlook Strategy and goals
Outlook Strategy and goals It is the key aim of TruScreen Group Ltd to be month to month cash flow positive by 31 March 2025 For personal use only Lowering COGS Lowering Market Growth operating costs 12
Slide 13: The Global Market
For personal use only Market The Global 13
Slide 14: The Global Market
The Global Market For personal use only Cervical cancer is the Globally, 604 000 new fourth most common cases and 342 000 cancer in women globally deaths were recorded in 2020 The highest rates are About 90% of these in Africa, Central deaths occurred in low- America and South- and middle-income Eas
Slide 15: TruScreen's presence and markets
TruScreen’s presence and markets* RUSSIA 48M POLAND & 13M CENTRAL For personal use only ASIA 13M European Union: China UZBEKISTAN 477M CE Mark ISO 13485 SAUDI 12M MEXICO 46M 11M VIETNAM Registered with: 36M • TGA, Australia • MHRA, UK INDONESIA • NMPA, China SOUTHERN 96M & CENTRAL • SFDA, Saudi Arab
Slide 16: Market Expansion
For personal use only Market Expansion 16
Slide 17: Market Expansion
Market Expansion TruScreen sales grow 27% YOY, exceeding China and APAC CAGR forecasts for HPV screening (10%). For personal use only Business Market Insights June 2023: The Asia Pacific CIN & HR-HPV 1 treatment market is expected to grow from US$ 2,738.94 million in 2023 to US$ 3,949.99 million by
Slide 18: Device installations and SUS pull through
Device installations and SUS pull through Where we are For personal use only 18
Slide 19: Market Expansion
19 Market Expansion 1 2 3 For personal use only MAXIMISE EXPAND MAXIMISE GROW Seize the COGA Blue Expand markets in, Grow commercial Book & CSCCP national Mexico, Vietnam, presence in South East, guideline inclusion and Zimbabwe and East South and Central Asia, focus on Key Provinces Africa, Middle
Slide 20: China
For personal use only China 20
Slide 21: China
Over 477 million women of screening age, with 158 million women needing to be screened each year* For personal use only High government China support for cervical TruScreen’s largest market cancer screening and No 1 Focus for Sales Made in China status from 2021 – preferred market access in China –
Slide 22: Market Expansion China
Market Expansion China For personal use only TruScreen listed in COGA TruScreen Listed in (China Obstetrics and CSCCP (China Society Gynaecology Association) for Colposcopy and Blue Book Cervical Pathology) Guideline Installation in key opinion This listing was leading hospital in re-inforced by Jia
Slide 23: TruScreen's largest market and growth opportunity
TruScreen’s largest market and growth opportunity For personal use only Consumable (Single Estimated potential for Use Sensor) sales for this to grow to 290 Growing recurring revenue FY24 were a 24% Single Use Sensors per device - from 85 to increase on FY23 per device per month > 129 consumable sal
Slide 24: China potential for SUS pull through growth
China potential for SUS pull through growth For personal use only The devices in China: Currently have an average pull 1 through of 129 SUS per device per month. The potential average pull 2 through of SUS exceeds 290 per month. Key accounts reach 500+ SUS 3 pull through. 24
Slide 25: TruScreen FY2025 Growth Pipeline
TruScreen FY2025 Growth Pipeline Target > 150 devices in full commercial use by March 31 2025 For personal use only Device Installation Pipeline 97 25 10 • 97 hospitals have installed TruScreen and actively use our hospitals hospitals tenders device for cervical cancer screening • 25 hospitals have
Slide 26: China Key Objectives
China Key Objectives Increase Provincial Pricing Approvals from 11 to 16 For personal use only Increase commercial user installation base from 97 to 150 Focus on Key Expansion Provinces Jiangsu, Zhejiang and Guangzhou Increase SUS pull through (SUS per device per month) from 129 to 290 Accelerate Ad
Slide 27: Vietnam
For personal use only Vietnam 27
Slide 28: Market opportunity
Market opportunity 36 million women of Booming economy screening age* and middle class For personal use only No centralised Ministry Of Health (MOH) screening programs has listed TruScreen on the National Technical List of approved technologies This reduces the hospital purchasing approval time from
Slide 29: Vietnam Key Objectives
Vietnam Key Objectives Focus on Public Hospitals For personal use only Target list of 64 Hospitals identified with installations to roll out across FY 25 and FY26 Rollout commenced with the first 10 Devices and 1800 Single Use Sensors purchased Aim is 25 devices installed by March 31, 2025 Source: h
Slide 30: Mexico
For personal use only Mexico 30
Slide 31: Market opportunity
Market opportunity TruScreen using this For personal use only COFEPRIS approval approval to focus on a 46 million women of granting access to public tender for Mexico City screening age health sector, where over (Greater Mexico City has a 70% of women receive population of 22m and a medical care GDP
Slide 32: Eastern Europe and Central Asia
For personal use only Eastern Europe and Central Asia 32
Slide 33: Poland
TruScreen won the top award in the Mother and Child Institute challenge for healthcare companies. This is the largest public hospital For personal use only network for womens health in Poland. Poland 13 million women of As a result of this GE Health screening age introduced TruScreen to a major priv
Slide 34: Uzbekistan and Russia and Central Asia
TruScreen is in discussions with the Uzbekistan Ministry of Uzbekistan Health and representatives from the office of the 12 million women of President for use as a For personal use only screening solution in regional screening age centres and remote communities. TruScreen’s Russian distributor is ex
Slide 35: Africa and Middle East
For personal use only Africa and Middle East 35
Slide 36: For personal use only
TruScreen continues to work Re–validation of TruScreen with the Ministry of Health for government programs Zimbabwe and the National Aids is to be completed Council to expand on our following which new 17 million women of work in Masvingo province, tenders will be submitted For personal use only whe
Slide 37: Saudi Arabia
Commercial rollout A 500 patient trial found commenced in FY24, with that TruScreen was 25% Saudi Arabia Private Health more sensitive (83.3% v Insurance reimbursement 66.7%) than Pap in 11 million women of for TruScreen available detecting cervical cancer For personal use only from most Private scr
Slide 38: South and South East Asia
For personal use only South and South East Asia 38
Slide 39: Indonesia and South & SE Asia
TruScreen distributor PT Mursmedic has commenced Indonesia has no national product registration in screening program but a Indonesia Indonesia to enable growing business and validation trials in the worlds 96 million women of largest Islamic Country, middle class seeking access to modern health For
Slide 40: Technology Improvements And Cost Reductions
For personal use only Technology Improvements And Cost Reductions 40
Slide 41: Technology Improvements
Technology Improvements TruScreen has implemented or is actively engaged in the For personal use only following device and Single Use Sensor improvement programs Working with key suppliers in China and USA to improve the Identifying and validating performance of sputtering - the improved optical and
Slide 42: Technology improvements
For personal use only Technology Building upon the previous Self Calibration Software Development, to enable an improvements increase of the in-field service interval of the device from 18 months to 3 years or more Target 96% of devices self-calibrating for a minimum of 3 years 42
Slide 43: Operating cost improvements
Operating cost improvements TruScreen has implemented or is actively engaged in the following head office cost improvements: For personal use only Reduced head Reduced head office office employee contractor day/hour Conducted and continuing numbers commitments to conduct a review of all suppliers (e
Slide 44: Key Takeaways
For personal use only Key Takeaways 44
Slide 45: Key takeaways
Key takeaways For personal use only TruScreen China sales TruScreen targeting cash growth outperforming Market expansion to flow break even by end of growth rates of continue with China the March 2025 competing technologies key focus (e.g. HPV DNA) Expand on government Target Govt and NGO Technology
Slide 46: Q&A Thank you
For personal use only Q&A Thank you 46
Slide 47: A World Without Cervical Cancer
For personal use only A World Without Cervical Cancer www.truscreen.com 47
Slide 48: Contact Us For More Information
Contact Us For More Information For personal use only Martin Dillon Guy Robertson CEO Chief Financial Officer M - +61 449 115 065 M – +61 407 983 270 E – martindillon@truscreen.com E – guyrobertson@truscreen.com TruScreen TruScreen Suite 3, Level 3, 18-20 Orion Rd Suite 3, Level 3, 18-20 Orion Rd La
Slide 49: Disclaimers
Disclaimers • This presentation has been prepared by TruScreen Group Limited (the “Company”) and is dated 27 March 2024. This presentation contains summary information about the Company and its activities which is current as at the date of this presentation. The information in this presentation is o
Slide 50: References
References For personal use only A World Without 1. WHO, HPV and Cervical Cancer Fact sheet, 11 November 2020, https://www.who.int/news- room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer 2. WHO Cervical Cancer Elimination Modelling Consortium (CCEMC), 2020 Cervical Cancer 3. Hum
Slide 51: About TruScreen Technology
For personal use only About TruScreen Technology 51
Slide 52: TruScreen transformation of cervical cancer screening
TruScreen transformation of cervical cancer screening Moving from multi-step, expensive screening to Point-of-Care Solution Specimen Label, Packaging Slide Microscopic Communication Fixation Staining Interpretation Reporting Collection And Transport Preparation Examination Of Results For personal us
Slide 53: Trusted Clinical Performance
Trusted Clinical Performance For personal use only High sensitivity in High specificity in Extensive body of detecting CIN2+* detecting CIN2+* clinical evidence TruScreen® has been TruScreen® has been Over 40,000 found to be as sensitive found to be more women in clinical in detecting CIN2+ as speci
Slide 54: Why choose TruScreen?
Why choose TruScreen®? Liquid Based HPV DNA* Cytology (LBC) For personal use only Real time results ✓ Low infrastructure costs ✓ Strong clinical results ✓ ✓ ✓ Objective results ✓ Low training threshold ✓ Portable ✓ No cell or tissue samples taken ✓ * HPV DNA, Human Papilloma Virus DNA test 54
TruScreen Group — Shareholder Meeting (September 2024) on 6ix